ES2107357A1 - Sales de peptidos con poliesteres carboxi-terminados. - Google Patents

Sales de peptidos con poliesteres carboxi-terminados.

Info

Publication number
ES2107357A1
ES2107357A1 ES09450004A ES9450004A ES2107357A1 ES 2107357 A1 ES2107357 A1 ES 2107357A1 ES 09450004 A ES09450004 A ES 09450004A ES 9450004 A ES9450004 A ES 9450004A ES 2107357 A1 ES2107357 A1 ES 2107357A1
Authority
ES
Spain
Prior art keywords
salts
carboxy
peptides
terminated polyesters
excess
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES09450004A
Other languages
English (en)
Other versions
ES2107357B1 (es
Inventor
Francis Gowland Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of ES2107357A1 publication Critical patent/ES2107357A1/es
Application granted granted Critical
Publication of ES2107357B1 publication Critical patent/ES2107357B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Polyesters Or Polycarbonates (AREA)

Abstract

SALES DE PEPTIDOS CON POLIESTERES CARBOXI-TERMINADOS, EN CONCRETO NUEVAS SALES CONSTITUIDAS POR UN CATION DERIVADO DE UN PEPTIDO QUE CONTIENE AL MENOS UN GRUPO BASICO Y DE UN ANION DERIVADO DE UN POLIESTER CARBOXI-TERMINADO. LA INVENCION PROPORCIONA TAMBIEN PROCESOS PARA PREPARAR DICHAS SALES, ASI COMO EL USO DE ESTAS ULTIMAS EN LA PREPARACION DE COMPOSICIONES FARMACEUTICAS DE LIBERACION PROLONGADA. LAS SALES DE LA INVENCION POSEEN DIVERSAS PROPIEDADES UTILES EN LA FORMULACION DE COMPOSICIONES FARMACEUTICAS DE LIBERACION PROLONGADA, INDEPENDIENTEMENTE DE QUE LAS SALES SE ENCUENTREN EN FORMA PURA O EN MEZCLA CON UN EXCESO DEL PEPTIDO EN SU FORMA LIBRE NO ENLAZADA O CON UN EXCESO DEL POLIESTER LIBRE.
ES09450004A 1992-05-28 1993-05-25 Sales de peptidos con poliesteres carboxi-terminados. Expired - Fee Related ES2107357B1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters

Publications (2)

Publication Number Publication Date
ES2107357A1 true ES2107357A1 (es) 1997-11-16
ES2107357B1 ES2107357B1 (es) 1998-10-16

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09450004A Expired - Fee Related ES2107357B1 (es) 1992-05-28 1993-05-25 Sales de peptidos con poliesteres carboxi-terminados.

Country Status (33)

Country Link
US (3) US5889110A (es)
JP (1) JPH08501064A (es)
KR (1) KR100293882B1 (es)
AT (1) AT407702B (es)
AU (1) AU682310B2 (es)
BE (1) BE1006143A3 (es)
CA (1) CA2136751C (es)
CH (2) CH690491A5 (es)
CZ (1) CZ292449B6 (es)
DE (2) DE4392401T1 (es)
DK (1) DK176134B1 (es)
ES (1) ES2107357B1 (es)
FI (1) FI112603B (es)
FR (1) FR2691631B1 (es)
GB (3) GB9211268D0 (es)
GR (1) GR1001550B (es)
HK (1) HK133097A (es)
HU (1) HUT70177A (es)
IE (1) IE74715B1 (es)
IL (1) IL105710A (es)
IT (1) IT1271139B (es)
LU (1) LU88559A1 (es)
MC (1) MC2330A1 (es)
NL (1) NL195056C (es)
NO (1) NO311006B1 (es)
NZ (1) NZ252268A (es)
RU (1) RU2152225C1 (es)
SE (1) SE501970C2 (es)
SG (1) SG44645A1 (es)
SK (1) SK280320B6 (es)
TW (1) TW223018B (es)
WO (1) WO1993024150A1 (es)
ZA (1) ZA933358B (es)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2003535122A (ja) * 2000-06-02 2003-11-25 ザイコス インク． 生物活性物質のための送達システム
EP1353701B1 (en) * 2000-10-31 2011-12-21 PR Pharmaceuticals, Inc. Methods for producing compositions for enhanced delivery of bioactive molecules
CA2451187C (en) * 2001-06-22 2012-08-14 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
CN101785861B (zh) * 2001-10-19 2014-08-13 爱德士实验室公司 用于药理活性化合物的可控释放的可注射组合物
NZ533436A (en) * 2001-11-14 2007-10-26 Alza Corp Catheter injectable depot compositons and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
ATE507816T1 (de) * 2001-11-14 2011-05-15 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
EP1344520B1 (en) * 2002-03-15 2007-10-03 Alrise Biosystems GmbH Microparticles and method for their production
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
DK1532985T3 (en) 2002-06-25 2016-12-05 Takeda Pharmaceuticals Co PROCEDURE FOR PREPARING A COMPOSITION WITH LONG-TERM RELEASE
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN1684663A (zh) * 2002-07-31 2005-10-19 阿尔萨公司 可注射的多模式聚合物储库组合物以及其用途
AU2002359397B2 (en) * 2002-07-31 2009-01-29 Durect Corporation Injectable depot compositions and uses thereof
CN102516417B (zh) 2002-09-06 2014-12-10 天蓝制药公司 用于传递治疗剂的以环糊精为基础的聚合物
JP2006508127A (ja) 2002-11-06 2006-03-09 アルザ・コーポレーション 制御された放出性デポー剤配合物
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
SG192300A1 (en) 2003-01-28 2013-08-30 Ironwood Pharmaceuticals Inc Methods and compositions for the treatment of gastrointestinal disorders
DK1610822T4 (en) * 2003-04-02 2019-01-14 Ares Trading Sa Liquid pharmaceutical FSH and LH formulations together with a nonionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
CA2526099C (en) * 2003-06-20 2013-02-05 Ares Trading Sa Freeze-dried fsh / lh formulations
WO2005034852A2 (en) 2003-08-26 2005-04-21 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
EP1682537B1 (en) 2003-11-05 2012-03-28 SARcode Bioscience Inc. Modulators of cellular adhesion
CA2548822C (en) 2003-12-08 2015-08-11 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8945598B2 (en) 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20090155176A1 (en) 2007-10-19 2009-06-18 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
EP2237770A4 (en) 2007-12-26 2011-11-09 Gel Del Technologies Inc BIOCOMPATIBLE PROTEIN PARTICLES, PARTICLE DEVICES AND METHODS THEREOF
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
JP5855568B2 (ja) 2009-09-15 2016-02-09 セルリアン・ファーマ・インコーポレイテッド 癌の治療法
US8378105B2 (en) 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
BR112012014947A2 (pt) * 2009-12-22 2019-09-24 Takeda Pharmaceuticals Co formulação de liberação prolongada,e, método para produzir a formulação de liberação prolongada
DE102010003615A1 (de) 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
EP3566719A1 (en) 2010-05-18 2019-11-13 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
UY33465A (es) * 2010-06-25 2012-01-31 Takeda Pharmaceutical Formulacion de liberacion sostenida
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012250776B2 (en) 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
KR102157608B1 (ko) 2012-07-25 2020-09-18 에스에이알코드 바이오사이언스 인코포레이티드 Lfa-1 저해제 및 그의 다형체
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
ES2804702T3 (es) * 2013-03-04 2021-02-09 Besins Healthcare Lu Sarl Composiciones farmacéuticas secas que comprenden nanopartículas de agente activo unidas a partículas de portador
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US20160220630A1 (en) 2013-10-10 2016-08-04 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
EP4331670A3 (en) 2015-01-07 2024-05-29 Tonix Pharma Limited Magnesium-containing oxytocin formulations and methods of use
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US10653744B2 (en) 2016-01-11 2020-05-19 Bausch Health Ireland Limited Formulations and methods for treating ulcerative colitis
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
US20210154147A1 (en) * 2018-10-19 2021-05-27 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
KR20220140711A (ko) 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
WO2022029220A1 (en) 2020-08-05 2022-02-10 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
AU2022323754A1 (en) 2021-08-05 2024-02-08 Medincell S.A. Pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052510A2 (en) * 1980-11-18 1982-05-26 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
EP0058481A1 (en) * 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
EP0350246A2 (en) * 1988-07-05 1990-01-10 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
EP0467389A2 (en) * 1990-07-19 1992-01-22 University Of Kentucky Research Foundation Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (es) * 1989-07-28 1992-01-15 Debiopharm Sa
EP0489743A1 (en) * 1990-07-03 1992-06-17 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0052510A2 (en) * 1980-11-18 1982-05-26 Syntex (U.S.A.) Inc. Microencapsulation of water soluble polypeptides
EP0058481A1 (en) * 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
EP0350246A2 (en) * 1988-07-05 1990-01-10 Takeda Chemical Industries, Ltd. Sustained release microcapsule for water soluble drug
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
EP0467389A2 (en) * 1990-07-19 1992-01-22 University Of Kentucky Research Foundation Drug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHARMACEUTICAL RESEARCH, Vol. 8, n‘ 5, 1991, pßginas 584-587. H. OKADA et al. "Sustained Pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of Leuprolide acetate" * Todo el documento * *
PROCEED. INTERN. SYMP. CONTROL. REF. BIOACT. MATER., Vol. 14, 1987, pßginas 99-100. J.R. LAWTER et al. "Drug release from poly(Glycolide-CO-DL-Lactide) microcapsules" * Todo el documento * *
ZIEKENHUISFARMACIE, Vol. 4, n‘ 2, 1998, pßginas 54-56. F.G. HUTCHINSON et al. "Biodegradable polymers for the delivery of polypeptides and proteins" * Todo el documento * *

Also Published As

Publication number Publication date
WO1993024150A1 (en) 1993-12-09
GB2282066B (en) 1996-11-06
CA2136751A1 (en) 1993-12-09
GB2282066A (en) 1995-03-29
US20020198315A1 (en) 2002-12-26
ES2107357B1 (es) 1998-10-16
IL105710A0 (en) 1993-09-22
IE74715B1 (en) 1997-07-30
FR2691631A1 (fr) 1993-12-03
SG44645A1 (en) 1997-12-19
FI945553A0 (fi) 1994-11-25
GR1001550B (el) 1994-04-29
SE9404115L (sv) 1994-11-28
ITMI931099A1 (it) 1994-11-27
US5889110A (en) 1999-03-30
LU88559A1 (fr) 1995-04-05
NZ252268A (en) 1996-12-20
AU682310B2 (en) 1997-10-02
DK135394A (da) 1994-11-28
TW223018B (en) 1994-05-01
HUT70177A (en) 1995-09-28
DK176134B1 (da) 2006-09-18
IE930358A1 (en) 1993-12-01
FR2691631B1 (fr) 1995-06-09
GB9423366D0 (en) 1995-01-25
SK280320B6 (sk) 1999-11-08
NO944535L (no) 1995-01-25
SK143494A3 (en) 1995-07-11
CH688911A5 (de) 1998-05-29
ZA933358B (en) 1994-09-15
HK133097A (en) 1997-10-24
BE1006143A3 (fr) 1994-05-24
ITMI931099A0 (it) 1993-05-27
CH690491A5 (de) 2000-09-29
DE4392401B4 (de) 2007-05-16
GB9211268D0 (en) 1992-07-15
JPH08501064A (ja) 1996-02-06
RU2152225C1 (ru) 2000-07-10
FI945553A (fi) 1995-01-25
CZ293794A3 (en) 1995-03-15
IT1271139B (it) 1997-05-27
IL105710A (en) 2001-03-19
GB9309645D0 (en) 1993-06-23
NO944535D0 (no) 1994-11-25
FI112603B (fi) 2003-12-31
DE4392401T1 (de) 1997-07-24
SE9404115D0 (sv) 1994-11-28
US6034175A (en) 2000-03-07
CA2136751C (en) 2006-10-31
SE501970C2 (sv) 1995-07-03
HU9403371D0 (en) 1995-02-28
NL195056C (nl) 2003-07-01
ATA901993A (de) 2000-10-15
KR100293882B1 (ko) 2001-09-17
CZ292449B6 (cs) 2003-09-17
NL9320034A (nl) 1995-04-03
MC2330A1 (fr) 1994-05-31
RU94046097A (ru) 1996-09-20
AU4084793A (en) 1993-12-30
AT407702B (de) 2001-05-25
NO311006B1 (no) 2001-10-01

Similar Documents

Publication Publication Date Title
ES2107357A1 (es) Sales de peptidos con poliesteres carboxi-terminados.
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
HK1002017A1 (en) Lyospheres comprising gonadotropin
EP0366638A3 (en) Neuromodulatory peptide
ID21956A (id) Asam n-(aril dan atau heteroarilasetil) amino ester, komposisi farmasi yang mengandungnya, dan metoda untuk menghambat pelepasan betha-amiloid peptida dan atau sintesanya dengan menggunakan senyawa tersebut
CA2163361A1 (en) Therapeutic substituted guanidines
IL104716A (en) 7-1-oxo-2- (substituted mercapto)-3- phenylpropyl) amino| octahydro-6-pyrido £2, 1-a| benzazepine- 4-carboxylic acid derivatives and analogs, their preparation and pharmaceutical compositions containing them for inhibiting enkephalinase and ace
BR9807076B1 (pt) "uso de acetato de glatirâmero para a fabricação de medicamento para o tratamento de esclerose múltipla e composição farmacêutica"
CA2138451A1 (en) Sugar-coated pharmaceutical dosage unit
TR199700999T1 (xx) Askomisinler.
MY128260A (en) Cyclopentane-and-pentene-b-amino acids
AU3850997A (en) Immunologically active proteins of borrelia burgdorferi, coded nuclein acids of such and their use in test kits and vaccines
CA2047802A1 (en) Pharmaceutical compositions
ES8605769A1 (es) Un procedimiento para la preparacion de un peptido
EP0714404A4 (en) ANTI-FLAMMABLE PEPTIDES
CA2066532A1 (en) Pharmaceutical compositions
CA2011874A1 (en) Sdk peptides, a preparation process of the same and therapeutic compositions containing them
ATE224724T1 (de) Pharmazeutische zusammensetzung enthaltend peptide für die inhibierung der immunoglobulin- rezeptor interaktion
CA2210871A1 (en) Human dnase i variants
DE3665462D1 (en) Pharmacologically active peptides
ES8800924A1 (es) Procedimiento para la obtencion de benzotiopiranonas
AU7308296A (en) Stabilised pharmaceutical compositions containing dobutamine
RU96118282A (ru) Пептиды для ингибирования высвобождения пепсина

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19971116

Kind code of ref document: A1

Effective date: 19971116

FD1A Patent lapsed

Effective date: 20101018